← board
CLDWW
distress 8/10 · high distress / dilution risk$0.01today0% from 52w high
Lead: solid tumors (NSCLC
Revenue
pre-revenue
Liquidity
$7M
Runway
0.4 yrs
Shares 1y
+464%
Overview
- Market Cap
- $104.28K
- Enterprise Value
- $-6.15M
- Volume
- 1.00K
- 52 Week Range
- $0.01 – $0.01
- Total Shares
- 19.31M
- Float Shares
- 19.00M
- RVOL
- 1.00x
- Beta
- 1.30
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- Q4 2026Guided 70%regulatory submissionFiled (NDA/BLA)CLD-401 · File IND for CLD-401, a systemic targeted genetic medicine delivering IL-15 superagonist to tumor microenvironment.SEC 8-K
- first half of 2025readoutPhase 1CLD-101 · Interim clinical data from Phase 1 trial in collaboration with City of Hope expected.SEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 1/2CLD-101 · Phase 1b/2 open-label trial of CLD-101 in newly diagnosed high-grade glioma expected to start.SEC 8-K
- 2024-10-17withdrawalNYSE American to delist CLDI WS warrants due to low trading priceSEC 8-K
- 2024-09-30fda agreementCLD-101 · FDA cleared Northwestern University's IND application for CLD-101 Phase 1b/2 trial in high-grade glioma.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — solid tumors (NSCLC
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.